Boryung Corporation (003850.KS)
KRW 10260.0
(-3.39%)
KRW 10260.0
(-3.39%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 189.8 Billion KRW | 15.3% |
| 2022 | 164.62 Billion KRW | 48.32% |
| 2021 | 110.99 Billion KRW | 16.23% |
| 2020 | 95.49 Billion KRW | 12.27% |
| 2019 | 85.05 Billion KRW | 12.17% |
| 2018 | 75.82 Billion KRW | 24.88% |
| 2017 | 60.72 Billion KRW | -17.28% |
| 2016 | 73.4 Billion KRW | 51.48% |
| 2015 | 48.46 Billion KRW | -3.7% |
| 2014 | 50.32 Billion KRW | 12.44% |
| 2013 | 44.75 Billion KRW | 0.5% |
| 2012 | 44.53 Billion KRW | 1.74% |
| 2011 | 43.76 Billion KRW | 14.28% |
| 2010 | 38.3 Billion KRW | -0.95% |
| 2009 | 38.66 Billion KRW | 2.96% |
| 2008 | 37.55 Billion KRW | 65.52% |
| 2007 | 22.68 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 251.14 Billion KRW | 10.07% |
| 2024 Q1 | 228.17 Billion KRW | 20.22% |
| 2023 Q3 | 199.19 Billion KRW | 15.33% |
| 2023 Q2 | 172.71 Billion KRW | 3.58% |
| 2023 FY | 189.8 Billion KRW | 15.3% |
| 2023 Q1 | 166.74 Billion KRW | 1.29% |
| 2023 Q4 | 189.8 Billion KRW | -4.71% |
| 2022 Q2 | 138.81 Billion KRW | 3.07% |
| 2022 FY | 164.62 Billion KRW | 48.32% |
| 2022 Q4 | 164.62 Billion KRW | 11.12% |
| 2022 Q3 | 148.14 Billion KRW | 6.72% |
| 2022 Q1 | 134.67 Billion KRW | 21.34% |
| 2021 Q2 | 115.32 Billion KRW | 12.7% |
| 2021 Q3 | 118.23 Billion KRW | 2.53% |
| 2021 Q4 | 110.99 Billion KRW | -6.12% |
| 2021 FY | 110.99 Billion KRW | 16.23% |
| 2021 Q1 | 102.32 Billion KRW | 7.16% |
| 2020 Q3 | 101.71 Billion KRW | 3.44% |
| 2020 FY | 95.49 Billion KRW | 12.27% |
| 2020 Q4 | 95.49 Billion KRW | -6.12% |
| 2020 Q1 | 86.92 Billion KRW | 2.19% |
| 2020 Q2 | 98.33 Billion KRW | 13.13% |
| 2019 FY | 85.05 Billion KRW | 12.17% |
| 2019 Q4 | 85.05 Billion KRW | 6.54% |
| 2019 Q3 | 79.83 Billion KRW | 5.04% |
| 2019 Q2 | 76 Billion KRW | -2.57% |
| 2019 Q1 | 78 Billion KRW | 2.87% |
| 2018 Q4 | 75.82 Billion KRW | -8.72% |
| 2018 Q2 | 70.46 Billion KRW | 6.69% |
| 2018 FY | 75.82 Billion KRW | 24.88% |
| 2018 Q1 | 66.05 Billion KRW | 8.78% |
| 2018 Q3 | 83.07 Billion KRW | 17.89% |
| 2017 Q1 | 77 Billion KRW | 4.9% |
| 2017 Q2 | 72.75 Billion KRW | -5.51% |
| 2017 Q4 | 60.72 Billion KRW | -15.85% |
| 2017 Q3 | 72.15 Billion KRW | -0.82% |
| 2017 FY | 60.72 Billion KRW | -17.28% |
| 2016 Q4 | 73.4 Billion KRW | 0.0% |
| 2016 FY | 73.4 Billion KRW | 51.48% |
| 2015 Q2 | 48.98 Billion KRW | -8.08% |
| 2015 FY | 48.46 Billion KRW | -3.7% |
| 2015 Q4 | 48.46 Billion KRW | 3.74% |
| 2015 Q3 | 46.71 Billion KRW | -4.64% |
| 2015 Q1 | 53.29 Billion KRW | 5.9% |
| 2014 Q3 | 45.56 Billion KRW | 4.44% |
| 2014 Q4 | 50.32 Billion KRW | 10.45% |
| 2014 FY | 50.32 Billion KRW | 12.44% |
| 2014 Q1 | 46.73 Billion KRW | 4.43% |
| 2014 Q2 | 43.62 Billion KRW | -6.66% |
| 2013 Q3 | 46.05 Billion KRW | 10.58% |
| 2013 Q4 | 44.75 Billion KRW | -2.83% |
| 2013 FY | 44.75 Billion KRW | 0.5% |
| 2013 Q1 | 44.53 Billion KRW | 0.01% |
| 2013 Q2 | 41.65 Billion KRW | -6.47% |
| 2012 Q2 | 40.02 Billion KRW | -4.96% |
| 2012 Q1 | 42.1 Billion KRW | -3.79% |
| 2012 FY | 44.53 Billion KRW | 1.74% |
| 2012 Q4 | 44.53 Billion KRW | 1.05% |
| 2012 Q3 | 44.06 Billion KRW | 10.11% |
| 2011 Q3 | 42.04 Billion KRW | 14.63% |
| 2011 FY | 43.76 Billion KRW | 14.28% |
| 2011 Q1 | 40.95 Billion KRW | 6.93% |
| 2011 Q4 | 43.76 Billion KRW | 4.1% |
| 2011 Q2 | 36.67 Billion KRW | -10.45% |
| 2010 Q1 | 43.13 Billion KRW | 11.54% |
| 2010 FY | 38.3 Billion KRW | -0.95% |
| 2010 Q4 | 38.3 Billion KRW | 9.2% |
| 2010 Q3 | 35.07 Billion KRW | -5.84% |
| 2010 Q2 | 37.24 Billion KRW | -13.64% |
| 2009 Q1 | 36.58 Billion KRW | -2.58% |
| 2009 FY | 38.66 Billion KRW | 2.96% |
| 2009 Q4 | 38.66 Billion KRW | 17.61% |
| 2009 Q3 | 32.87 Billion KRW | 8.84% |
| 2009 Q2 | 30.2 Billion KRW | -17.44% |
| 2008 Q2 | 28.53 Billion KRW | 5.87% |
| 2008 Q4 | 37.55 Billion KRW | 15.97% |
| 2008 Q3 | 32.38 Billion KRW | 13.5% |
| 2008 FY | 37.55 Billion KRW | 65.52% |
| 2008 Q1 | 26.95 Billion KRW | 18.78% |
| 2007 FY | 22.68 Billion KRW | 0.0% |
| 2007 Q1 | 20.91 Billion KRW | 0.0% |
| 2007 Q3 | 20.88 Billion KRW | -2.84% |
| 2007 Q4 | 22.68 Billion KRW | 8.64% |
| 2007 Q2 | 21.49 Billion KRW | 2.79% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -329.89% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | -61.054% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | -108.197% |
| HANDOK Inc. | 94.46 Billion KRW | -100.928% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -793.494% |
| Yuhan Corporation | 284.75 Billion KRW | 33.345% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | -63.185% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -1067.412% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 34.281% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -486.107% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -207.504% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -874.51% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -526.831% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | -292.588% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -329.89% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -507.558% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -439.583% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | -294.376% |
| JW Holdings Corporation | 147.58 Billion KRW | -28.604% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | -124.295% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 27.398% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -78.908% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -251.992% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -603.037% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -483.813% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | -72.915% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -329.89% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | -0.616% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 21.42% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -78.908% |
| Yuhan Corporation | 284.75 Billion KRW | 33.345% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | -51.505% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | -206.205% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 26.953% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -78.908% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | -138.441% |
| Korea United Pharm Inc. | 49.14 Billion KRW | -286.239% |
| CKD Bio Corp. | 69.08 Billion KRW | -174.754% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | -80.633% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | -168.477% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | -251.116% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -251.992% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 2.546% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | -233.978% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -207.504% |
| JW Lifescience Corporation | 23.39 Billion KRW | -711.184% |